Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with RA and received 3 mg/kg of Inflectra as an IV infusion followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Inflectra was administered in combination with methotrexate. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with SpA and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with PA and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with RA and received 3 mg/kg of Inflectra as an IV infusion followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Inflectra was administered in combination with methotrexate. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with SpA and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with RA and received 3 mg/kg of Inflectra as an IV infusion followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Inflectra was administered in combination with methotrexate. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with SpA and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with SpA and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with RA and received 3 mg/kg of Inflectra as an IV infusion followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Inflectra was administered in combination with methotrexate. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with SpA and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with RA and received 3 mg/kg of Inflectra as an IV infusion followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Inflectra was administered in combination with methotrexate. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with SpA and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with RA and received 3 mg/kg of Inflectra as an IV infusion followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Inflectra was administered in combination with methotrexate. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with RA and received 3 mg/kg of Inflectra as an IV infusion followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Inflectra was administered in combination with methotrexate. Participants were observed for 2 years in this study.

Adult participants included in this arm were diagnosed with SpA and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult and pediatric participants included in this arm were diagnosed with UC and received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.

Adult participants diagnosed with moderately to fistulizing active CD received 5 mg/kg of Inflectra as an IV infusion followed by additional 5 mg/kg infusion at 2 weeks (for moderate to severely active CD) and at 2 weeks and 6 weeks (for fistulizing active) after the first infusion. Participants who responded to the treatment received additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by infusions every 8 weeks or infusion of 5 mg/kg if signs and symptoms of the disease. Pediatric participants diagnosed with CD received 5 mg/kg given as an IV infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Participants were observed for 2 years in this study.